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HIV infection has a high prevalence in antenatal at-
tendees in South Africa. In the annual seroprevalence 
survey conducted through the National Department of 
Health from 2005, the prevalence in the Western Cape 
province was 15.7%.1 Here, a pilot zidovudine (ZDV)-
based prevention of mother-to-child transmission 
(PMTCT) programme began in 1999,2 and has gradually 
been expanded since January 2001. Since April 2003 
the PMTCT interventions have been available at all 
public sector antenatal service facilities in the prov-
ince (300 antenatal clinics and 53 delivery centres and 
hospitals) and 350 primary health care clinics where 
infant follow-up occurs. Attendees are offered volun-
tary, confidential counselling and testing (VCT) and if 
HIV positive, antiretrovirals (ARVs) for the mother and 
infant. Uptake was reported as 97% in 2006 (Status 
Report – Prevention of Mother-to-Child Transmission 
Programme, 14 July 2006, HIV/AIDS/STI Directorate, 
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Objectives. To evaluate efficacy of the antenatal, intrapartum and postnatal antiretroviral components of a 
public service prevention of mother-to-child (PMTCT) programme in infants. 
Design. Analysis of prospectively collected screening data of demographic and MTCT-related interventions and 
HIV infection status of infants identified through HIV-specific DNA polymerase chain reaction. 
Setting. Tygerberg Children’s Hospital, Western Cape, South Africa. 
Subjects. HIV-infected women and their infants identified through participation in a public service PMTCT pro-
gramme were referred for possible participation in a prospective study of isoniazid prophylaxis. 
Interventions. Key components of the programme include voluntary counselling and testing, administration 
of zidovudine to the mother from between 28 and 34 weeks’ gestation and to the newborn infant for the first 
week, single-dose nevirapine to the mother in labour and to the newborn shortly after birth, and free formula 
for 6 months.
Main outcome measures. Number and percentage of HIV-infected infants and extent of exposure to antenatal, 
intrapartum and postnatal antiretrovirals.
Results. Of 656 infants with a median age of 12.6 weeks, screened between 1 April 2005 through May 2006, 
39 were HIV-infected, giving a transmission rate of 5.9% (95% confidence interval (CI) 4.4 - 8.0%). Antenatal 
prophylaxis was significantly associated with reduced transmission (odds ratio (OR) 0.43 (95% CI 0.21 - 0.94)) 
as opposed to intrapartum and postpartum components (p=0.85 and p=0.84, respectively). In multivariable 
analysis the antenatal component remained significant (OR=0.40 (95% CI 0.19 - 0.90)).
Conclusions. The antenatal phase is the most important antiretroviral component of the PMTCT programme, 
allowing most opportunity for intervention. 
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Western Cape). Follow-up of mother and infant, co-
trimoxazole from 6 weeks of age and modified infant 
feeding practices are also important components. The 
majority of women (95%) choose formula feeding, 
which is provided free for the first 6 months. 
The initial ARV intervention was single-dose nevirap-
ine (sd-NVP) to mother and infant, introduced after the 
success of the HIVNET 012 study.3 Since mid-2003, ZDV 
was added from 34 weeks’ gestation for the mother 
and for a week for the neonate.4 In early 2006, an-
tenatal ZDV from 28 weeks was gradually introduced. 
With the advent of the national antiretroviral rollout 
in 2004, all pregnant women with a CD4 count below 
200 cells/µl were offered highly active antiretroviral 
therapy (HAART). 
PACTG 1041 is a prospective phase III clinical trial eval-
uating the efficacy of isoniazid (INH) primary prophy-
laxis in HIV-exposed infected and uninfected infants. 
Through screening for this trial at Tygerberg Children’s 
Hospital (TCH), we had the opportunity to evaluate the 
PMTCT programme in referred infants.
HIV-exposed infants between 3 and 4 months of age 
were referred for study participation from health care 
facilities in the urban and semi-rural areas close to 
TCH. Referring clinics were requested not to refer in-
fants exposed to TB. Infants were pre-screened by lay 
counsellors and nurses for eligibility to enrol in PACTG 
1041. Exclusion criteria included exposure to tubercu-
losis and not receiving bacille Calmette-Guérin (BCG) 
immunisation within the first week of life. Eligible sub-
jects were entered onto a screening log, comprising the 
dataset for the present report.
A medical doctor undertook formal screening. Note 
was taken of the extent of participation in the PMTCT 
programme and whether the mother received HAART 
in pregnancy. 
Those receiving either antenatal HAART or ZDV were 
categorised as having received antenatal prophylaxis. 
Intrapartum prophylaxis was either ZDV or NVP or 
both. Postnatal intervention to the neonate was either 
ZDV or NVP or both.
HIV DNA polymerase chain reaction (PCR) was per-
formed on all exposed infants eligible for the trial. All 
samples were tested in duplicate. For discordant re-
sults, the test was repeated in duplicate.
Simple percentages were used to estimate rates of 
transmission and 95% confidence intervals (CIs) were 
based on the score method.  Medians and interquar-
tile ranges (IQR) were used to summarise continuous 
data. Logistic regression was used to evaluate the ef-
fectiveness of PMTCT components. Odds ratios (ORs) 
were calculated through the logistic regression model 
and 95% CIs are based on the profile likelihood. For 
antenatal HAART, Fisher's exact test was used because 
of the small cell size. In multivariable logistic regres-
sion analysis, we evaluated all two-way and three-way 
interactions between the three PMTCT programme 
components and found no statistically significant in-
teractions, and therefore present a multivariable model 
that includes main effects for the three components. 
All tests are two-sided at the 5% significance level and 
are not adjusted for multiple comparisons. Analyses 
were done using SAS 9.1 (Cary, NC, USA). 
Permission to conduct P1041 and to report on ante-
natal interventions was obtained from the Committee 
for Pharmaceutical Trials, Stellenbosch University, and 
the Medicines Control Council of South Africa. The trial 
was approved by the National Institute of Allergy and 
Infectious Diseases (NIAID) according to the Office of 
Human Rights Protection, National Institutes of Health 
guidelines.
Between 1 April 2005 and 31 May 2006, 773 infants 
were referred for pre-screening. Seven infants were 
excluded because their mothers were HIV-negative 
and had been referred in error. One hundred and ten 
HIV-exposed infants were excluded at pre-screening, 
of whom 52 (47.3%) had known exposure to tubercu-
losis.5 Other common reasons included the infant being 
too old for participation in the INH trial (15), BCG given 
after 7 days of life (15) and family relocating (7). 
Six hundred and fifty-six infants were entered onto 
the screening log and are reported on here. The median 
age (IQR) of infants was 12.6 (11.0 - 13.6) weeks and 
that of mothers 26 (23 - 30) years. Thirty-nine of 656 
infants had a positive HIV DNA PCR, giving a transmis-
sion rate of 5.9% (95% CI 4.4 - 8.0%). Two hundred 
and seventy-eight (85.8%) of 324 mothers who were 
asked decided on exclusive formula feeding.
Data on transmission and extent of participation in the 
PMTCT programme are shown in Table I. We evaluated 
the antenatal, intrapartum and postnatal components 
of the programme separately, using logistic regression 
(Table II).  We found that antenatal prophylaxis was 
significantly associated with a reduction in rate of 
transmission (OR 0.43 (95% CI 0.21 - 0.94), p=0.035) 
as opposed to intrapartum and postnatal components 
(p=0.85 and p=0.84, respectively). 
The results of fitting a multivariable logistic regression 
model to the data, which included the three compo-
nents of the PMTCT programme, are shown in Table III. 
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The antenatal component of the PMTCT regimen re-
mained significant in the multivariable model, indicat-
ing that it is an independent predictor of decreased 
transmission (OR 0.40 (95% CI 0.19 - 0.90), p=0.027). 
Of 57 mothers with CD4 cell counts below 200/µl 
receiving HAART, only 1 (1.8% (95% CI 0.3 - 9.3%)) 
transmitted HIV to her infant versus 26 of 453 with 
CD4 counts >200/µl not receiving HAART (5.7% (95% 
CI 3.9 - 8.3%), p=0.34).
Fifty-one (7.8%) mother/infant pairs with missing 
PMTCT information were excluded from the above 
analyses. Of these, only 1 woman (2.0% (95% CI 3.5 
- 10.3%)) transmitted HIV to her infant.
There is little information on vertical transmission in the 
absence of intervention in South Africa. Transmission 
rates vary between 15% and 34%.6,7 In the ZDV-based 
pilot programme in Khayelitsha, Western Cape, the 
transmission rate was 11%.2 In a study evaluating sd-
NVP in different South African settings, the transmission 
rate in Paarl, a recruitment site for P1041, was 8.3% at 
3 weeks of age.8 The combination of antenatal ZDV from 
28 weeks and sd-NVP under optimal circumstances is 
associated with a transmission rate as low as 1.1%.4 
Our data confirm a relatively effective PMTCT pro-
gramme despite only 53% actually participating in all 
components of the programme. Importantly, an addi-
tional 25% received antenatal ARVs. A multi-faceted 
intervention programme means that there are many 
opportunities for intervention, as opposed to one rely-
ing on only a single intervention such as sd-NVP, which, 
if missed, severely compromises efficacy. The World 
Health Organization has endorsed the programme as 
practised in the Western Cape.9 Our data confirm the 
relative importance of antenatal as opposed to perina-
tal or postnatal intervention. The transmission rate of 
5.9% was achieved due to concerted efforts to facili-
tate success of the programme despite widespread per-
ceived obstacles to initial implementation.10 Although 
we did not record duration of antenatal ARVs in each 
case, 75% of mothers were reported to have received 
≥2 weeks of therapy, defined as adequate by the pro-
gramme (personal communication – Pauline Pieters, 
PMTCT Co-ordinator, 20 September 2006). 
An important preliminary finding in our study is that 
among women with CD4 cell counts <200/µl, only 1 of 
57 mothers on HAART (1.8%) transmitted HIV, as op-
posed to 26 (5.7%) of 453 mothers receiving ZDV. Al-
though this was not statistically significant, we expect-
PMTCT component Adjusted OR (95% CI) p-value*
Antenatal   0.40 (0.19 - 0.90) 0.027
Intrapartum  1.26 (0.57 - 2.89) 0.57
Postnatal  1.05 (0.46 - 2.60) 0.91
*Likelihood ratio test.
TABLE III. MULTIVARIABLE ANALYSIS
     Received component/total (%)
    Infant not      Infant      OR  
Programme component  HIV infected  HIV infected (95% CI) p-value†
Antenatal PMTCT  483/568 (85.0) 27/38 (71.1) 0.43 (0.21 - 0.94) 0.035
Intrapartum PMTCT  380/568 (66.9) 26/38 (68.4) 1.07 (0.54 - 2.25) 0.85
Postnatal PMTCT 425/568 (74.8) 29/38 (76.3) 1.08 (0.52 - 2.48) 0.84
Antenatal HAART* 56/564 (9.9) 1/38 (2.6) 0.25 (0.01 - 1.52) 0.24
*Exact CI and Fisher’s exact test p-value provided for antenatal HAART due to the small number of infections among those who received antenatal HAART.
†Likelihood ratio test from logistic regression model, except for antenatal HAART which is a Fisher’s exact test.
TABLE II. UNIVARIATE ANALYSES
DISCUSSION
    Infants HIV-infected  
 Screened (N (%))* (N (% of screened))  
PMTCT 656 39 (5.9)
Full participation 348 (53.0) 21 (6.0)
Antenatal only 105 (16.0) 4 (3.8)
Antenatal + postnatal (no intrapartum) 42 (6.4) 1 (2.4)
Antenatal + intrapartum 15 (2.3) 1 (6.7)
Postnatal only 39 (5.9) 4 (10.3)
Intrapartum only 18 (2.7) 1 (5.6)
Intrapartum + postnatal 25 (3.8) 3 (12.0)
None 13 (2.0) 3 (23.1)
No data 51 (7.8) 1 (2.0)
*Percentages do not add to 100.0 due to rounding.
Antenatal = either ZDV or HAART; intrapartum and postnatal = sd-NVP, ZDV. 
TABLE I. EXTENT OF PARTICIPATION OF MOTHERS AND THEIR INFANTS IN THE PMTCT PROGRAMME AND HIV 
TRANSMISSION RATES
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ed more transmission among these mothers because of 
their low CD4 counts before initiation of HAART.  
There are a number of limitations to our study. We did 
not record the mothers’ CD4 counts; rather, we as-
sumed that they were appropriately managed accord-
ing to the PMTCT guidelines. Also, we only screened in-
fants whose mothers expressed interest in their infants 
participating in the INH study. Nevertheless, our data 
are similar to those of the Department of Health, West-
ern Cape, which reports a transmission rate of 6.2% 
(personal communication – Pauline Pieters, PMTCT Co-
ordinator, 20 September 2006). 
 
There were missing PMTCT data on 7.8% of screened 
mother/infant pairs, and the transmission rate was low 
in this group (2.0%). If we assume that none of these 
women received any component of PMTCT or that 
these women received all components of PMTCT, the 
conclusions drawn here remain unchanged.
The antenatal ARV component is extremely important 
for reduction of MTCT and reduces intra-uterine infec-
tion, For example, Lallemant et al. showed that initiat-
ing ZDV at 28 weeks was far more effective than at 
35 weeks and was not compensated for by extending 
postnatal ZDV for 6 weeks.11 Nevertheless, the intra-
partum and postnatal components also have an im-
portant role. For example, Wade et al. showed that in 
the absence of ZDV, perinatal transmission of HIV was 
26.6% (95% CI 21.1 - 32.7%).12 When ZDV was be-
gun antenatally, the transmission rate was 6.1% (95% 
CI 4.1 - 8.9%). Administration of postnatal ZDV alone 
within 48 hours of life had a transmission rate of 9.3% 
(95% CI 4.1 - 17.5%), indicating the importance of the 
postnatal component.12 Gray et al. found postnatal sd-
NVP to be slightly more effective than ZDV for 6 weeks 
when neither antenatal nor intrapartum ARVs could be 
given.13
The public service PMTCT programme in the Western 
Cape has successfully reduced the vertical transmis-
sion of HIV. The antenatal ARV component is critical 
for success. 
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